14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -2.695 3 days ( 16.90 % )
Last Price $0.0300 0 %
High/ Low $0.0300 - $0.0300 -20.33%
Chg 7 Days -16.90 % $0.0361 $0.0300
Chg 30 Days -14.29 % $0.0350 $0.0300
Chg 12 mos -96.00 % $0.750 $0.0300
Trend - 3 mos -4.81 % Width: 98.07 %
Trend - 12 mos -86.76 % Width: 138.35 %
Pred. range - 3 mos $0.0283 - $0.0560 -5.68 % - 86.81 %
Pred. range - 12 mos N/A - $0.0153 -100.00 % - -49.03 %
Short MA avg 3 mos Buy Apr 29, 2024 - 5 days
Long MA avg 3 mos Sell Apr 16, 2024 - 14 days
Short/Long MA avg 3 mos Sell Apr 24, 2024 - 8 days
Short MA avg 12 mos Sell Apr 24, 2024 - 8 days
Long MA avg 12 mos Sell Apr 16, 2024 - 14 days
Short/Long MA avg 12 mos Sell Nov 30, -1 - N/A days
Pivot Short Buy May 02, 2024 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings. Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis dis... CMRA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT